CCM
LYEL icon

CAAS Capital Management’s Lyell Immunopharma LYEL Stock Holding History

CAAS Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,000
Closed -$1.48M – 969
2021
Q3 		$1.48M Hold
5,000
– – 0.03% 412
2021
Q2 		$1.62M Buy
+5,000
New +$1.64M 0.03% 440

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

CAAS Capital Management's LYEL Position: Q4 2021 in Review

CAAS Capital Management sold out of Lyell Immunopharma (LYEL) in Q4 2021, closing a stake of 5,000 shares — an estimated $1.48M sold.

CAAS Capital Management first reported a position in LYEL in Q2 2021 and held it in 2 quarters. The position peaked at $1.62M in Q2 2021. 77 funds tracked by Wall St. Rank hold LYEL as of Q4 2021.

  • CAAS Capital Management reported no remaining Lyell Immunopharma position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 5,000 Lyell Immunopharma shares in Q4 2021, an estimated $1.48M.
  • CAAS Capital Management first reported a position in Lyell Immunopharma in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's Lyell Immunopharma position peaked at $1.62M in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.